Search the archive

A patient safety mechanism born from tragedy is now set to cover every emergency department in England.

The US approval of Fayuvi marks a historic moment for a devastating childhood condition with no previously licensed treatment.

Kier's three-storey all-electric build for the University of Salford signals growing private investment in NHS-adjacent health infrastructure.

Oveporexton's US approval sets the clock running on a potential MHRA review and NHS access debate for a condition with few good options.

The agreement positions J&J at the frontier of a gene-delivery approach that could reshape autoimmune treatment without the complexity of cell harvesting.

The Oxford-based cancer immunotherapy specialist will gain a US public listing through a deal that rescues Neuphoria's stranded shareholders.

The triple-G agonist achieved 22.6% weight loss in phase 3 trials, yet failed to confirm the cardiovascular risk reduction investors had anticipated.

Health authorities urge the public to use certified eye protection as the UK prepares for its first significant solar eclipse in years.

A new England-wide funding scheme targets arthritis and back pain patients with rapid, specialist-led clinics designed to accelerate return to work.

Europe's medicines regulator has launched a phased review of daraxonrasib, raising hopes for a disease with few effective treatments.

A major planning submission next to The Royal London Hospital underscores private capital's deepening interest in health and life-sciences infrastructure.

The sodium channel-targeting drugmaker's public market debut signals growing investor appetite for non-addictive pain therapeutics.

A new annual accolade will honour outstanding healthcare leadership, with the winner unveiled at a major December event.

A spike in American physician practice insolvencies signals systemic stress that international investors and UK-listed health groups cannot ignore.

BMS deepens its Nvidia partnership to accelerate drug discovery with an AI infrastructure play that could reshape R&D timelines.

The AI-driven diagnostics firm absorbs its oncology genomics partner three years after their initial collaboration.

As tick season peaks, updated UKHSA guidance on Lyme disease diagnosis and treatment carries implications across primary care and public health.

Soficitinib meets its primary endpoint in nonsegmental vitiligo, advancing a crowded race for the first approved TYK2 therapy in the condition.

Contractor GRAHAM is building an 8,500 sqm clinical research innovation hub in Belfast, due to open in spring 2027.

Deals of $100 million or more are dominating venture capital flows into digital health, reshaping who benefits and who gets left behind.

A new facility offering lab, office and prototyping space signals fresh ambitions for health-sector clustering outside London.

NHSBSA data reveals a 7% year-on-year surge in accepted applications, pointing to deepening affordability pressures across England.

New EMA initiatives aim to close persistent gaps in how medicines are developed and regulated for female patients.

Lipfendra's clearance marks a landmark shift in cardiovascular medicine and raises questions for UK prescribing pathways.

A proposed US fee schedule reduction for 2027 carries lessons for UK healthcare markets navigating similar value-versus-volume tensions.

Eli Lilly's latest acquisition marks the most significant mainstream validation yet for psychedelic-derived psychiatric treatments.

A long-term NHS drive aims to save thousands of lives by overhauling how sepsis is identified and treated across England.

A new WHO report projects a dramatic surge in cancer incidence, intensifying pressure on already-strained healthcare systems worldwide.

A formal partnership will embed specialist oncology expertise into Mid Cheshire's landmark new hospital development.

A deep-dive on the forces driving healthcare mergers and acquisitions through 2024–2025 — from private equity's pivot to add-ons and physician platforms, to the drag of elevated interest rates, tighter antitrust scrutiny, and where the next wave of deals is likely to land.

A US generic approval for the single-dose flu drug baloxavir marboxil raises questions about access, pricing, and NHS formulary strategy.

The Emergency Use Listing marks a first for BDBV diagnostics, with implications for global outbreak preparedness and UK biosecurity planning.

A damning independent review has prompted a multi-pronged funding and governance package targeting the UK's struggling maternity and neonatal infrastructure.

The construction group secures a major NHS oncology facility build for Guy's and St Thomas', marking a significant financial turnaround.

The UK regulator has approved Incyte's PD-1 inhibitor ZYNYZ for a neuroendocrine skin malignancy with historically poor outcomes.

The EMA's human medicines committee recommended six new treatments and two biosimilars at its latest monthly meeting.

A supplemental US approval for the CRISPR-based therapy Casgevy broadens its eligible population — with significant implications for UK commissioning.

A new briefing reveals the hidden workforce cost of mandating A&G as a substitute for hospital referrals.

As summer temperatures climb, the UK's health infrastructure braces for predictable but often underestimated seasonal demand.

From app-based triage to clinical notetaking, the NHS is pushing AI tools into frontline use at scale.